**Chapter 3**

*Type 2 Diabetes - From Pathophysiology to Modern Management*

[45] Zelniker TA, Wivioytt SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcomes trials. The Lancet. 2018;**393**:31-39. DOI: 10.1016/

S0140-6736(18)32590-X

peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;**368**:1696-1705

y Nutrición. 2016;**63**:560-568

2008;**57**:1470-1481

2011;**34**:392-397

2007;**261**:32-43

[37] Muñoz-Garach A, Díaz-Perdigones C, Tinahones FJ. Gut microbiota and type 2 diabetes mellitus. Endocrinología

[38] Cani P, Bibiloni R, Knauf C, Waget A, Neyrinck A, Delzenne N. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes.

[39] Pussinen P, Havulinna A, Lehto M, Sundvall J, Salomaa V. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care.

[40] Abdul-Ghani M, Norton L, DeFronzo R. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocrine Reviews. 2011;**32**:515-531

[41] Wright E, Hirayama B, Loo F. Active sugar transport in health and disease. Journal of Internal Medicine.

[42] Bakris G, Fonseca V, Sharma K, Wright E. Renal sodium–glucose transport: Role in diabetes mellitus and potential clinical implications. Kidney International. 2009;**75**:1272-1277

[43] Schwartz S, Epstein S, Corkey B, Grant S, Gavin J, Aguilar R. The time is right for a classification system for diabetes: Rationale and implications of the b-cell–centric classification schema.

Diabetes Care. 2016;**39**:179-186

[44] Standars of Medical Care in Diabetes 2018 (ADA). Pharmacologic approaches to glycemic treatment. Diabetes Care. 2018;**41**(Suppl. 1):

**42**

S73-S85
